Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
Otsuka Pharmaceutical to Acquire Mindset Pharma
Mindset Pharma is being sold to a big pharma player, Otsuka Pharmaceutical. Otsuka and Mindset already had a previous relationship, with the pharma giant investing $5 million into developing Mindset’s programs. Now the pair have taken the next step.
Otsuka will acquire all of Mindset’s shares for approximately CAD $80 million in an all-cash transaction. Each Mindset shareholder will receive $0.75 in cash for each share of Mindset.
New Johns Hopkins Study Shows Psilocybin Helps Long Term Mental Health
A new study from Johns Hopkins adds further evidence that natural psilocybin use promotes positive long-term effects on well-being measures like emotion regulation, mental flexibility, and reduced neuroticism.
Published by the Johns Hopkins Center for Psychedelic and Consciousness Research, including authors like Roland Griffiths and Matthew Johnson, the study reviewed a sample of over 2,000 individuals intending to use psilocybin outside of clinical research settings.
Cybin to Acquire Small Pharma
Cybin has signed a deal to acquire Small Pharma. The all-share transaction will have Cybin acquire Small Pharma’s Phase 2 DMT trial for depression, a study that posted very impressive results earlier this year. Along with Cybin’s existing DMT CYB-004 program and its CYB-003 trial for depression, this acquisition boosts Cybin further up the ladder of top-tier psychedelic medicine firms.
Usona Publishes Results of Phase 2 Psilocybin Trial for Depression
Usona is a non-profit medical research organization, running a variety of trials and research on psychedelic medicine. The institute has been sponsoring this long-running trial, the largest Phase 2, double-blind, placebo-controlled study evaluating a single dose of psilocybin to treat major depressive disorder.
The trial dosed 104 adults between December 2019 and June 2022, across a variety of sites. The results were published in Jama and showed that psilocybin was well-tolerated with solid efficacy results.
